U.S. government extends RFP-2 contract with Bavarian Nordic

05-Oct-2007

The U.S. government has extended the RFP-2 contract that was awarded to Bavarian Nordic in 2004. Within the scope of the extension, Bavarian Nordic will initiate a larger Phase II study with IMVAMUNE® in people diagnosed with atopic dermatitis. The contract extension has a value of USD 15 million.

The additional clinical studies will be performed within the contract period, which has been extended until 2010. However the main part of the revenue is expected in the end of 2008 and beginning of 2009.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances